Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integration of Clinical, Radiomics, and 2.5D Deep Learning-Based Multiple Instance Learning Features for Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunotherapy and Chemotherapy: A Multicenter Comparative Study

NCT07181850 is registered in ClinicalTrials.gov with Nanjing Medical University as lead sponsor.

NCT NCT07181850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07181850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integration of Clinical, Radiomics, and 2.5D Deep Learning-Based Multiple Instance Learning Features for Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunotherapy and Chemotherapy: A Multicenter Comparative Study
Lead sponsor
Nanjing Medical University
Phase
Observational
Overall status
Completed
Start date
January 1, 2019
Completion date
July 31, 2025
Enrollment
363 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma, pathological complete response